A recent article in the Journal of Clinical Oncology has surely caught the eyes of many in the world of integrative and alternative medicine. Isabel Bairati and colleagues report on a randomized trial in which they gave head and neck cancer patients in their experimental group supplemental vitamin E and β-carotene during and after radiation therapy. 1 Patients receiving the supplements had lower rates of side effects from radiation therapy than the control group did, as might be expected with the use of antioxidants. When information about the prooxidant effects of β-carotene in presumably oxidizing environments was published a few years into the trial, β-carotene supplements were eliminated from the study and only vitamin E was given. Vitamin E alone did not protect against radiationinduced side effects. By the end of the study, it was found that patients who had received both β-carotene and vitamin E, as well as those who received vitamin E alone, had a nonsignificantly higher risk of local recurrence. An earlier publication on the same study found that while the overall risk of second primary cancers after 8 years was similar between the control and supplemented groups, the supplemented groups (with or without β-carotene) had higher rates of second primaries during the supplementation period, which extended for 3 years beyond the end of radiation therapy. Both studies imply a negative effect of these antioxidants on head and neck cancer.
An editorial comment by Camphausen et al in the same issue as the more recent study makes several interesting points: they acknowledge that the phytochemical antioxidants probably are not present in sufficient concentration and are not sufficiently powerful free radical scavengers to be able to counteract the primary and secondary free radical species produced directly by radiation therapy. 2 They speculate that the antioxidants may suppress continued free radical production arising from the inflammatory response that follows radiation therapy, which could perhaps impede antitumor activity, although it is not known if this inflammatory response actually occurs in tumor tissue. The effects of antioxidants are certainly complicated by the fact that, as Camphausen et al acknowledge, most "antioxidants," particularly the phytochemical antioxidants, are not simply antioxidants but also trigger complex signal transduction pathways, which may ultimately result in tumor cell death, though a few promote tumor cell survival. The editorial warns that patients should "avoid unnecessary supplementation during and after radiotherapy."
Camphausen et al go on to conclude that improving the therapeutic index of radiation therapy through use of antioxidants is a reasonable and, in fact, commendable goal, suggesting that further attempts in this area should be carried out in cancers in which there is effective salvage therapy. This strategy would guarantee that if particular antioxidants should result in protection of tumor tissue, patients will not have a decrement in survival as a result of a therapy that may reduce treatment regimen side effects to a manageable level. We discuss this idea and other topics related to tumor protection in a commentary in this issue, based on the history and current research on the pharmacological antioxidant and normal tissue cytoprotectant amifostine. We especially emphasize the need to adapt the harsh modern regimens of chemoradiation and high-dose chemotherapy for bone marrow transplant to the needs of patients unable or unwilling to tolerate their side effects, by improving their therapeutic index with the use of amifostine and, potentially, phytochemical antioxidants. These may offer alternatives to amifostine, which, although it is definitely efficacious in a number of chemo and radiation side effects, is also expensive, logistically difficult, and frequently toxic. An article in the current issue of Integrative Cancer Therapies by Sunila and Kuttan explores the potential of a botanical as a radioprotectant, taking the initial step of evaluating its radioprotective effects on normal tissue in an animal model.
One concern that we have with the Journal of Clinical Oncology editorial by Camphausen et al is that the main message that many physicians will take away from it is not the idea that exploration of the cytoprotectant effects of phytochemical antioxidants can be reasonably conducted in human trials and that it is a reasonable goal to explore management of radiation's side effects with natural agents that are low in toxicity. Rather, we suspect that many physicians will stop at the sentence that urges people to avoid unnecessary supplementation and generalize it to urge all cancer patients to avoid all supplemental and food-based antioxidants at all times. This is not a reasonable response. There are many natural antioxidants, and they have many effects. No reasonable integrative physician today would counsel a patient to take β-carotene and vitamin E-or even vitamin E alone-to help in dealing with the side effects of radiation therapy or to Editorial use as a long-term nutritional support for helping to thwart cancer recurrence.
In different combinations and in different therapeutic settings, though, even vitamin E has shown more positive effects. Vitamin E and pentoxifylline have shown improvement when administered after radiation therapy in superficial radiation-induced fibrosis in breast cancer patients and in healing of osteoradionecrosis in small trials; a recent review indicates several promising areas of research on the effects of this combination in radiation fibrosis. 3 A combination of vitamin E with interferon-α2a plus isotretinoin resulted in prolonged survival of head and neck cancer patients after radiation treatment in a phase II trial. 4 Other antioxidants (eg, melatonin) show evidence of being useful during radiation therapy: Lissoni observed better survival of melatonin-supplemented glioblastoma patients treated with whole-brain irradiation relative to control patients in a small trial. 5 As mentioned by Camphausen et al, some antioxidants could also be described as pleiotropic compounds that trigger a wide range of signal transduction pathways that may be useful in controlling cancer. Mark McCarty and I discuss some of these compounds at length in a review of multifocal angiostatic therapeutic strategies that employ a variety of natural compounds in addition to dietary modification. Clinical use of phytochemical antioxidants, especially of some of the pleiotropic supplements, remains a reasonable alternative, especially for the many cancer patients whose conventional therapies regularly fail to provide longterm survival or acceptable quality of life.
In a startling turnabout to some of the antiantioxidant publications that have recently hit the press, a new study by Qi Chen, Mark Levine, and colleagues at the National Institutes of Health points to a potential anticancer mechanism of high-dose intravenous vitamin C. 6 Levine has been a respected vitamin C researcher for years. This new study finds that vitamin C, in concentrations that could be achieved only by intravenous administration of ascorbate, selectively killed cancer cells and left normal cells untouched. By analyzing the type of cell death involved, they found that ascorbate in these concentrations acts as a prodrug that results in cancer cell destruction by generating hydrogen peroxide radicals. These radicals may be carried in the blood. Cancer cells were sensitive to small amounts of ascorbate (nevertheless too high to be achieved except by intravenous administration), while normal cells were insensitive to these high concentrations or even concentrations an order of magnitude higher. This is a convincing mechanistic demonstration that may underlie the effects reviewed in the March 2005 issue of this journal by Gonzalez et al 7 and originated by the classic observations of Linus Pauling. High-dose intravenous vitamin C, long a controversial topic in alternative medicine, has just taken on a new life, and we will be watching for more on the subject in the future. Interestingly, this provides one more reason the "antioxidant" vitamins are really misnamed; the range of effects that phytochemicals with antioxidant properties have in living systems has been expanding at a stunning rate with the discovery of their effects on multiple signal transduction pathways-and has now been extended to the generation of powerful free radicals. Our lead article in this issue, by Marja Verhoef and colleagues, is a systematic review of the literature on characteristics of cancer patients who use alternative medicine and the reasons that they give for such use. This literature has been growing over the years, and Verhoef et al point out the need to transform the field into a more direct and patient-focused analysis of the process that patients go through in making choices about alternatives, through the use of qualitative research techniques. Denise Hann and colleagues at the American Cancer Society as well as hospitals throughout the country provide their own insights into the patients who use complementary therapies, contrasting the beliefs and motivations of patients with breast cancer and those with prostate cancer.
Rag Pradeep and colleagues at Avestha Gengrain Technologies and Amala Cancer Research Institute, both in India, offer a brief educational review of the vascular endothelial growth factor (VEGF) family of angiogenic peptides, their receptors, and their emerging anticancer role, with a special look at the natural phytochemicals that have been found to interact with VEGF. With the increasing emphasis on signal transduction and molecular target therapies, this review gives the busy practitioner a succinct chance to catch up in this area.
Finally, Lisa Sprod and colleagues at the Rocky Mountain Cancer Rehabilitation Institute have contributed a well-illustrated article on the use of walking poles as part of breast cancer rehabilitation. This form of exercise, also referred to as Nordic walking or ski walking, is already popular in Europe and is beginning to garner more attention in the United States. The gentle strength and aerobic training it offers is also being investigated in other conditions and appears to be especially useful in reducing the impact of walking on the joints.
